"Designing Growth Strategies is in our DNA"

KRAS Inhibitors Market Size, Share & Industry Analysis, By Drug (Sotorasib, Adagrasib, Divarasib, Olomorasib, RMC-6236, KRAS G12D Inhibitors, and Others), By Disease Indication (Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, and Others), By Age Group (Pediatric and Adults), By Type (KRAS G12C Inhibitors, KRAS G12D Inhibitors, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail & Drug Store Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

Last Updated: July 06, 2026 | Format: PDF | Report ID: FBI117951

 

  • 2021-2034
  • 2025
  • 2021-2024
  • 190
Download Free Sample

    man icon
    Mail icon

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann